Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

INSIDE INFORMATION

GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR IMPLEMENTATION OF THE H SHARE FULL CIRCULATION

This announcement is made by Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司) (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to (i) the announcement of the Company dated 12 November 2025 in relation to the Company's submission of the CSRC Filing; and (ii) the announcement of the Company dated 11 May 2026 in relation to the issuance of the Filing Notice by the CSRC for the H share full circulation application of the Company (collectively, the "**Announcements**"). Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

LISTING APPROVAL BY THE STOCK EXCHANGE

The Board is pleased to announce that the Company has applied to the Listing Committee of the Stock Exchange for the approval (the "**Listing Approval**") of the listing of 71,786,608 H Shares (the "**Converted H Shares**") to be converted under the conversion of

71,786,608 Domestic Shares (the "**Conversion**") held by 12 Shareholders (the "**Listing**") and the permission to deal in the Converted H Shares. The Company is pleased to announce that the Listing Approval was granted by the Stock Exchange on 13 May 2026.

Shareholding Structure

The Conversion and the Listing will involve a total of 71,786,608 Domestic Shares of 12 participating shareholders and the number of the Converted H Shares held by such participating shareholders represents approximately 33.99% of the total issued shares of the Company as at the date of this announcement.

Set out below is the percentage holding in the Company in relation to the participating shareholders of the Domestic Shares upon completion of the Conversion and the Listing.

Name of participating shareholders	**Number of Domestic Shares to be converted into H Shares**	**Approximate percentage *(Note 1)* of the Company's total issued share capital *(Note 2)***
Dr. Liang Dongke (梁棟科)	12,042,854	5.70%
Ningbo Huaige Taiyi Equity Investment Partnership (Limited Partnership)* (寧波懷格泰益股權投資合夥企業（有限合夥）) ("**Huaige Taiyi**") *(Note 3)*	9,843,750	4.66%
Mr. Lin Sen (林森)	7,142,858	3.38%
Mr. Wang Ruiqin (王瑞琴)	7,142,858	3.38%
Mr. Chen Xing (陳星)	7,071,430	3.35%
Mr. Huang Chubin (黃楚彬)	7,071,430	3.35%
Ningbo Tongchuang Suwei Investment Partnership (Limited Partnership)* (寧波同創速維投資合夥企業（有限合夥）)	6,000,000	2.84%
Mr. Wang Kai (王鍇)	5,571,428	2.64%

Name of participating shareholders	Number of Domestic Shares to be converted into H Shares	Approximate percentage *(Note 1)* of the Company's total issued share capital *(Note 2)*
Ningbo Jiaying Enterprise Management Partnership (Limited Partnership)* (寧波嘉瑛企業管理合夥企業（有限合夥）) ("**Ningbo Jiaying**") *(Note 4)*	5,000,000	2.37%
Ningbo INT Investment Partnership (Limited Partnership)* (寧波瑛泰投資合夥企業（有限合夥）) ("**Ningbo INT**") *(Note 4)*	2,400,000	1.14%
Jingning INT Chuangqi Enterprise Management Partnership (Limited Partnership)* (景寧瑛泰創啟企業管理合夥企業（有限合夥）) ("**INT Chuangqi**") *(Note 4)*	1,261,400	0.60%
Jingning INT Chuangyuan Enterprise Management Partnership (Limited Partnership)* (景寧瑛泰創源企業管理合夥企業（有限合夥）) ("**INT Chuangyuan**") *(Note 4)*	1,238,600	0.59%
Total	**71,786,608**	**33.99%**

Notes:

(1) The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.

(2) The calculation is based on the total number of 211,200,000 shares of the Company in issue as of the date of this announcement.

(3) Huaige Taiyi is controlled corporations of Mr.Wang Kai.

(4) Ningbo Jiaying, Ningbo INT, INT Chuangqi and INT Chuangyuan are controlled corporations of Dr. Liang Dongke.

As at the date of this announcement and upon completion of the Conversion and the Listing, the share capital structure of the Company will be as follows:

Class of shares	As at the date of this announcement		Upon completion of the Conversion and the Listing	
	Number of shares	*Approximate percentage*	*Number of shares*	*Approximate percentage*
H Shares	139,413,392	66.01%	211,200,000	100.00%
Domestic Shares	71,786,608	33.99%	0	0.00%
Total	**211,200,000**	**100.00%**	**211,200,000**	**100.00%**

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and the Listing in compliance with the requirements under the Listing Rules and applicable laws, as and when appropriate. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC
13 May 2026

As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Dr. Song Yuan, Mr. Wang Ruiqin, Ms. Chen Hongqin and Mr. Zhang Hong as non-executive Directors, and Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.

* *For identification purposes only*